What is Inhibikase Therapeutics Inventory-to-Revenue?
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Inhibikase Therapeutics's Average Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil. Inhibikase Therapeutics's Revenue for the
three
months ended in Mar. 2024 was $0.00 Mil.
Inhibikase Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2024
stayed the same
from Dec. 2023 (0.00) to Dec. 2023 (0.00)
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inhibikase Therapeutics Inventory-to-Revenue Historical Data
The historical data trend for Inhibikase Therapeutics's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Inhibikase Therapeutics's Inventory-to-Revenue
For the Biotechnology subindustry, Inhibikase Therapeutics's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibikase Therapeutics's Inventory-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Inhibikase Therapeutics's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Inhibikase Therapeutics's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inhibikase Therapeutics's Days Inventory for the
three
months ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibikase Therapeutics Inventory-to-Revenue Related Terms
Thank you for viewing the detailed overview of Inhibikase Therapeutics's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Inhibikase Therapeutics (Inhibikase Therapeutics) Business Description
Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IKT has been successfully added to your 